High Performance Network Quality Criteria for Designation

Size: px
Start display at page:

Download "High Performance Network Quality Criteria for Designation"

Transcription

1 Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain Natinal Quality Frum apprved measures t determine HPN designatin. Thrugh the cmbined effrts f Medical Management and Quality Imprvement departments, AvMed determined that certain apprved quality measures were relevant fr particular HPN selected specialties. Fr the upcming year's HPN designatin, AvMed has selected t use quality measure data received frm the prir calendar year thrugh the first quarter f the current year. This ensures that an apprpriate number f care pprtunities is assigned t the prvider grups being measured. Prvider grups are assigned care pprtunities if they encunter an AvMed member that falls int the ppulatin fr a particular quality measure (i.e. denminatr ppulatin). Prvider grups are marked as achieving care pprtunities fr that ppulatin if they fulfill the care pprtunity particular t that measure (i.e. numeratr ppulatin). Asthma Drug Mgt {QM} is the number f patients with persistent asthma, aged 5 t 56 years, wh were prescribed an inhaled crticsterid r an acceptable alternative primary therapy asthma medicatin, expressed as a percentage f the ttal number f patients, aged 5 t 56 years, with persistent asthma. It excludes patients with a diagnsis f emphysema r chrnic bstructive pulmnary disease (COPD) any time prir t r during the measurement perid, based n claims included in the database. Vaccine {QM} is the number f members, aged 50 years and lder, wh received an influenza vaccinatin, expressed as a percentage f the ttal number f members aged 50 years and lder. Pneumnia Vaccine {QM} is the number f members, aged 65 years and lder, wh received a pneumnia vaccinatin, expressed as a percentage f the ttal number f members aged 65 years and lder. Cardilgy Annual Mnitring f Digxin CAD ACE Inhib r ARB CAD Antiplatelet Tx Annual Mnitring f Digxin {QM} indicates whether a patient, aged 18 years and lder, wh received at least 180 days f digxin medicatin therapy during the measurement year, had at least ne therapeutic mnitring event (lab tests) during that same perid. This excludes patients wh had an inpatient stay during the measurement year. This measure is based n the HEDIS measure Annual Mnitring fr Patients n Persistent Medicatins (MPM). CAD ACE Inhib r ARB {QM} is the number f patients with crnary artery disease tgether with diabetes and/r left ventricular systlic dysfunctin (LVSD), aged 18 years and lder, wh were prescribed ACE inhibitr r ARB therapy, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with crnary artery disease tgether with diabetes and/r left ventricular systlic dysfunctin (LVSD). CAD Antiplatelet Tx {QM} is the number f patients with crnary artery disease, aged 18 years and lder, wh were prescribed antiplatelet therapy, expressed as a percentage f the ttal number f patients, age 18 years and lder, with crnary artery disease. HPN Quality Criteria V Page 1 f 6

2 Cardilgy (cntinued) Endcrinlgy CAD Beta Blk 6 M Pst MI CAD Event LDL LT 100 CAD LDL Lwering Drug HF ACE Inhib r ARB HF Atrial Fib Warfarin HF Beta Blcker Tx HF LVF Assessment Vaccine Pneumnia Vaccine CAD LDL Lwering Drug Therapy Diabetes Eye Exam CAD Beta Blk 6MPstMI{QM}isthenumberf patients hspitalized and discharged alive with a diagnsis f acute mycardial infarctin (MI), aged 18 years and lder, wh received treatment with beta-blcker drugs fr six mnths fllwing discharge, expressed as a percentage f the ttal number f patients, aged 18 years and lder, hspitalized and discharged alive with a diagnsis f acute mycardial infarctin (MI). CAD LDL LT 100 {QM} is the number f patients with a cardivascular event r diagnsis f ischemic vascular disease, aged 18 t 75 years, wh had at least ne nn-zer lw density lipprtein chlesterl (LDL-C) lab result recrd in the database during the measurement year and the mst recent result value was less than 100 mg/dl, expressed as a percentage f the ttal number f patients, aged 18 t 75 years, with a cardivascular event r diagnsis f ischemic vascular disease and at least ne nn-zer LDL-C lab result recrd in the database during the measurement year. CAD LDL Lwering Drug {QM} is the number f patients with crnary artery disease, aged 18 years and lder, wh were prescribed a lipid-lwering drug, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with crnary artery disease. It excludes patients with an allergy r intlerance t lipid-lwering drugs, as well thse with a dcumented reasn (e.g., medical, patient chice, system) fr nt having lipid-lwering therapy prescribed. HF ACE Inhib r ARB {QM} is the number f patients with heart failure tgether with left ventricular systlic dysfunctin (LVSD), aged 18 years and lder, wh were prescribed ACE inhibitr r ARB therapy, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with heart failure alng with left ventricular systlic dysfunctin (LVSD). HF AtrialFib Warfarin {QM} is the number f patients with heart failure tgether with parxysmal r chrnic atrial fibrillatin, aged 18 years and lder, wh were prescribed warfarin therapy, expressed as a percentage f the ttal number f patients, age 18 years and lder, with heart failure alng with parxysmal r chrnic atrial fibrillatin. HF Beta Blcker Tx {QM}isthenumberf patients with heart failure tgether with left ventricular systlic dysfunctin (LVSD), aged 18 years and lder, wh were prescribed beta blcker therapy, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with heart failure alng with left ventricular systlic dysfunctin (LVSD). HF LVF Assessment {QM} is the number f patients with heart failure, aged 18 years and lder, wh had a left ventricular functin (LVF) assessment dne, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with heart failure. Vaccine {QM} is the number f members, aged 50 years and lder, wh received an influenza vaccinatin, expressed as a percentage f the ttal number f members aged 50 years and lder. Pneumnia Vaccine {QM} is the number members, a ed 65 years and lder, wh received a pneumnia vaccinatin, expressed as a percentage f the ttal number f members aged 65 years and lder. CAD LDL Lwering Drug Therapy {QM} indicates whether a patient with crnary artery disease (CAD), aged 18 years and lder, was prescribed a lipid-lwering drug. This excludes patients with an allergy r intlerance t lipid-lwering drugs, as well as thse with a dcumented reasn (e.g., medical, patient chice, system) fr nt having lipid-lwering therapy prescribed. This measure is based n AMA PCPI's measure Chrnic Stable Crnary Artery Disease Perfrmance Measure Set, Lipid Cntrl. Diabetes Eye Exam {QM} is the number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had an eye exam dne, expressed as a percentage f the ttal number f patients, aged 18 t 75 years, with type 1 r type 2 diabetes. HPN Quality Criteria V Page 2 f 6

3 Diabetes HbA1c LT 8% Diabetes HbA1c LT 8% {QM} is the number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had at least ne nn-zer HbA1c lab result recrd in the database during the measurement year and the mst recent result value was less than 8%, expressed as a percentage f the ttal number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had at least ne nn-zer HbA1c lab result recrd in the database during the measurement year. Endcrinlgy (cntinued) OB/GYN Diabetes HbA1c LT 9% Diabetes HbA1c Test Diabetes LDL LT 100 Diabetes Micralbumin Vaccine Pneumnia Vaccine Breast Cancer Screen Vaccine Osteprsis Pst Fx Mgt Diabetes HbA1c LT 9% {QM} is the number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had at least ne nn-zer HbA1c lab result recrd in the database during the measurement year and the mst recent result value was less than r equal t 9%, expressed as a percentage f the ttal number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had at least ne nn-zer HbA1c lab result recrd in the database during the measurement year. Diabetes HbA1c Test {QM} indicates whether a patient with type 1 r type 2 diabetes, aged 18 t 75 years, had a hemglbin A1c test perfrmed. This excludes patients with a previus diagnsis f plycystic varies, gestatinal diabetes, r sterid-induced diabetes. This measure is based n the HEDIS measure Cmprehensive Adult Diabetes (CDC). Diabetes LDL LT 100 {QM} is the number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had at least ne nn-zer lw density lipprtein chlesterl (LDL-C) lab result recrd in the database during the measurement year and the mst recent result value was less than 100 mg/dl, expressed as a percentage f the ttal number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had at least ne nn-zer LDL-C lab result recrd in the database during the measurement year. Diabetes Micralbumin {QM} is the number f patients with type 1 r type 2 diabetes, aged 18 t 75 years, wh had a micralbumin test dne r had evidence f treatment fr nephrpathy, expressed as a percentage f the ttal number f patients, aged 18 t 75 years, with type 1 r type 2 diabetes. Vaccine {QM} is the number f members, aged 50 years and lder, wh received an influenza vaccinatin, expressed as a percentage f the ttal number f members aged 50 years and lder. Pneumnia Vaccine {QM} is the number f members, aged 65 years and lder, wh received a pneumnia vaccinatin, expressed as a percentage f the ttal number f members aged 65 years and lder. Breast Cancer Screen {QM} is the number f wmen members, aged 42 t 69 years, wh had a mammgram dne during the measurement year r the year prir t the measurement year, expressed as a percentage f the ttal number f wmen members, aged 42 t 69 years at the end f the measurement perid. Vaccine {QM} is the number f members, aged 50 years and lder, wh received an influenza vaccinatin, expressed as a percentage f the ttal number f members aged 50 years and lder. Osteprsis Pst Fx Mgt {QM} is the number f wmen wh suffered a fracture, aged 67 years and lder, and received either a bne mineral density test (BMD) r a prescriptin fr a drug t treat r prevent steprsis within 6 mnths f the fracture, expressed as a percentage f the ttal number f wmen, aged 67 years and lder, wh suffered a fracture. HPN Quality Criteria V Page 3 f 6

4 OB/GYN (cntinued) Pneumnia Vaccine Pneumnia Vaccine {QM} is the number f members, aged 65 years and lder, wh received a pneumnia vaccinatin, expressed as a percentage f the ttal number f members aged 65 years and lder. Pulmnlgy Rheumatlgy Asthma Drug Mgt COPD Inhal Brnchdilate COPD Spirmetry Eval Vaccine Pneumnia Vaccine Rheum Arthritis DMARD Asthma Drug Mgt {QM} is the number f patients with persistent asthma, aged 5 t 56 years, wh were prescribed an inhaled crticsterid r an acceptable alternative primary therapy asthma medicatin, expressed as a percentage f the ttal number f patients, aged 5 t 56 years, with persistent asthma. It excludes patients with a diagnsis f emphysema r chrnic bstructive pulmnary disease (COPD) anytime prir t r during the measurement perid, based n claims included in the database. COPD Inhal Brnchdilat {QM} is the number f patients with chrnic bstructive pulmnary disease (COPD), aged 18 years and lder, wh were prescribed an inhaled brnchdilatr, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with chrnic bstructive pulmnary disease (COPD). COPD Spirmetry Eval {QM} is the number f patients with chrnic bstructive pulmnary disease (COPD), aged 18 years and lder, wh had a spirmetry evaluatin dne, expressed as a percentage f the ttal number f patients, aged 18 years and lder, with chrnic bstructive pulmnary disease (COPD). Vaccine {QM} is the number f members, aged 50 years and lder, wh received an influenza vaccinatin, expressed as a percentage f the ttal number f members aged 50 years and lder. Pneumnia Vaccine {QM} is the number f members, aged 65 years and lder, wh received a pneumnia vaccinatin, expressed as a percentage f the ttal number f members aged 65 years and lder. Rheum Arthritis DMARD {QM} is the number f patients with rheumatid arthritis, aged 18 years and lder, wh had at least ne ambulatry prescriptin dispensed fr a disease-mdifying antirheumatic drug (DMARD), expressed as a percentage f the ttal number f patients, aged 18 years and lder, with rheumatid arthritis. HPN Quality Criteria V Page 4 f 6

5 Criteria fr Vlume Requirements, Scring Criteria, and Prvider Grup Definitins Calculating HPN Perfrmance fr selected quality measures A prvider grup s perfrmance n quality is based n the number f achieved care pprtunities they received cmpared t the number achieved by the verall peer grup. The peer grup is defined as like specialists fr all cmbined prducts. Example Quality Measure Calculatin: Per Specialty - Cmbined Prducts Quality Measure # 1 Quality Measure # 2 Quality Measure # 3 Ttal Ttal Ttal Peer Grup % % % Results Ttal Quality Measure # 1 Quality Measure # 2 Quality Measure # 3 QM Cmbined Ttal Ttal Prvider Grup # Prvider Grup # Prvider Grup # 1 s achieved care pprtunities were belw the peer grup average s they did nt met the HPN criteria Prvider Grup # 2 s achieved care pprtunities were abve the peer grup average s they met the HPN criteria pprtunities met ( ) is calculated as the peer grup rate fr that particular quality measure multiplied against the ttal care pprtunities fr that particular prvider grup. Fr Quality Measure #1 being applied t Prvider Grup #1 abve, this wuld be calculated as 40% * 23 = 9 The final QM scre sums the ttal expected care pprtunities met and cmpares against the actual care pprtunities met fr that particular prvider grup fr the relevant quality measures. A prvider grup must have at least 20 ttal care pprtunities t be cnsideredfr measurement. HPN Quality Criteria V Page 5 f 6

6 Quality was measured fr sl practitiners, single specialty grup practices, and multi-specialty grup practices. In general, t meet the HPN quality criteria, a prvider grup must have: Ttal Opprtunities = 20 r greater Have a care pprtunities met equal t r greater than the expected care pprtunities met Sl Practitiners Defined as ne physician, wh will meet the quality criteria when the physician has 20 r mre ttal care pprtunities and has care pprtunities met that are equal t r greater than the expected care pprtunities met during the measuring perid. Single specialty grups Defined as having mre than ne physician practicing in the same specialty and billing with the same tax id number. The practice receives designatin in the High Perfrmance Netwrk when the grup has 20 r mre ttal care pprtunities, and has care pprtunities met that are equal t r greater than the expected care pprtunities met during the measuring perid. If the grup practice has fewer than 20 ttal care pprtunities r has care pprtunities met that are belw the expected pprtunities met, the grup will nt receive the High Perfrmance Netwrk designatin based n that measuring perid. Multi-specialty grups Defined as having mre than ne physician practicing in mre than ne HPN selected specialty and billing with the same tax id. Each specialty is evaluated separately and will receive designatin in the High Perfrmance Netwrk when that particular specialty has 20 r mre ttal care pprtunities, and has care pprtunities met that are equal t r greater than the expected care pprtunities met during the measuring perid. If the specialty grup has fewer than 20 ttal care pprtunities r has care pprtunities met that are belw the expected pprtunities met, the grup will nt receive the High Perfrmance Netwrk designatin based n that measuring perid. HPN Quality Criteria V Page 6 f 6

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070) Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure

More information

<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>:

<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>: Three Penn Plaza East Newark, NJ 07105-2200 HriznBlue.cm RE: 2015 Blue Physician Recgnitin (BPR) Prgram Dear : Hrizn Blue Crss Blue Shield

More information

Diabetes: HbA1c Poor Control (NQF 0059)

Diabetes: HbA1c Poor Control (NQF 0059) Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December

More information

HEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8

HEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8 HEDIS Healthcare Effectiveness Data & Infrmatin Set (HEDIS ) The HEDIS â audit cntains a cre set f perfrmance measures that prvide infrmatin abut custmer satisfactin, specific health care measures, and

More information

LTCH QUALITY REPORTING PROGRAM

LTCH QUALITY REPORTING PROGRAM 4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC)

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC) Measure Specific Guidelines fr Cmprehensive Diabetes Care (CDC) Descriptin: Members age 18-75 years f age with diabetes (Type 1 and Type 2)* that had all f the fllwing: *Members in hspice are excluded

More information

Measure Information Form

Measure Information Form Release Ntes: Measure Infrmatin Frm Versin 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Infrmatin Frm Perfrmance Measure Name:

More information

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface

More information

Weight Assessment and Counseling for Children and Adolescents (NQF 0024)

Weight Assessment and Counseling for Children and Adolescents (NQF 0024) Weight Assessment and Cunseling fr Children and Adlescents (NQF 0024) EMeasure Name Weight Assessment and EMeasure Id Pending Cunseling fr Children and Adlescents Versin Number 1 Set Id Pending Available

More information

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

Michigan Primary Care Transformation Project Performance Incentive Technical Manual Michigan Primary Care Transfrmatin Prject 2016 Perfrmance Incentive Technical Manual Fr Physician Organizatins, Physician Hspital Organizatins, Independent Practice Assciatins and Primary Care Practices

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26

More information

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009 CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

CDC Influenza Technical Key Points February 15, 2018

CDC Influenza Technical Key Points February 15, 2018 CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity

More information

Osteoporosis Fast Facts

Osteoporosis Fast Facts Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4

More information

AdvantEdge Healthcare Solutions: 2012 Physician Quality Reporting System (PQRS) Manual

AdvantEdge Healthcare Solutions: 2012 Physician Quality Reporting System (PQRS) Manual AdvantEdge Healthcare Slutins: 2012 Physician Quality Reprting System (PQRS) Manual This newsletter cntains the fllwing infrmatin: 1. Eligible Prfessinals Page 1 2. PQRI Basics Page 1 3. 2011 Reprting

More information

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Ontario s Referral and Listing Criteria for Adult Lung Transplantation Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral

More information

2018 CMS Web Interface

2018 CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS Web Interface V1.1 Page 1 f 27 12/15/2016 Cntents INTRODUCTION... 4 WEB INTERFACE SAMPLING

More information

QUALITY AND SAFETY MEASURES UPDATE January 2016

QUALITY AND SAFETY MEASURES UPDATE January 2016 CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:

More information

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CDC Influenza Division Key Points MMWR Updates February 20, 2014 CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

Cognitive enhancers for the treatment of Alzheimer s disease

Cognitive enhancers for the treatment of Alzheimer s disease Cmprehensive Research Plan: Cgnitive enhancers fr the treatment f Alzheimer s disease Pharmacepidemilgy Unit February 13 th, 2015 30 Bnd Street, Trnt ON, M5B 1W8 www.dprn.ca inf@dprn.ca 2 ODPRN Drug Class

More information

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit

More information

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights. HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline) Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control NQF 0075 Ischemic Vascular Disease (IVD): Cmplete Lipid Panel and LDL Cntrl Initial Patient Ppulatin: Numeratr(1): Numeratr(2): N Exclusin: Denminatr: D Exceptin: D Exclusin: Patients 18 years f age and

More information

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service) 2013 DATA COLLECTION GUIDE Summary Data Submissin Optimal Asthma Care (07/01/2012 t 06/30/2013 Dates f Service) Htline: 612-746-4522 E-mail: supprt@mncm.rg Data Prtal: https://data.mncm.rg/lgin MN Cmmunity

More information

Cambridge Breast Unit Protocols for anticoagulant management prior to breast or axillary biopsies or excisions.

Cambridge Breast Unit Protocols for anticoagulant management prior to breast or axillary biopsies or excisions. Prtcl CBU/POL/ JOINT POLICIES/008 Octber 2017 Prtcls fr anticagulant management prir t breast r axillary bipsies r excisins. 1. Scpe Fr use in the in bth screening and symptmatic breast services. 2. Purpse

More information

Adult Preventive Care Guidelines

Adult Preventive Care Guidelines Adult Preventive Care Guidelines Gundersen is yur partner fr better health. We want t wrk with yu t make sure that yu and yur family are as healthy as pssible. That can be accmplished best if we wrk tgether

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is

More information

BP Thresholds for Medical Review

BP Thresholds for Medical Review BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening and Fllw- Measure Steward: CMS Web Interface V1.0 Page 1 f 23 11/15/2016 Cntents INTRODUCTION... 3 WEB

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface IVD-2 (NQF 0068): Ischemic Vascular Disease (IVD): Use f Aspirin r Anther Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 20 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will: Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin

More information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered

More information

Evaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief

Evaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief Evaluatin f a Shared Decisin Making Interventin between Patients and Prviders t Imprve Menpause Health Outcmes: Issue Brief Key Findings Tablet technlgy can be successfully incrprated int primary practices

More information

Referral Criteria: Inflammation of the Spine Feb

Referral Criteria: Inflammation of the Spine Feb Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses

More information

Ischemic heart disease (angina/chest pain)

Ischemic heart disease (angina/chest pain) Ischemic heart disease (angina/chest pain) External resurces Stable angina: management NICE guidelines [CG126] Updated :Aug 2016 https://www.nice.rg.uk/guidance/cg126 Chest pain f recent nset [CG95] Nvember

More information

Influenza (Flu) Fact Sheet

Influenza (Flu) Fact Sheet Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

Pediatric and adolescent preventive care and HEDIS *

Pediatric and adolescent preventive care and HEDIS * Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.0 Page 1 f 23 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

Significance of Chronic Kidney Disease in 2015

Significance of Chronic Kidney Disease in 2015 1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care

More information

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select

More information

ACRIN 6666 Screening Breast US Follow-up Assessment Form

ACRIN 6666 Screening Breast US Follow-up Assessment Form Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

COPD Outreach Program

COPD Outreach Program COPD Outreach Prgram Wendy Laframbise, Advanced Practice Nurse Certified Respiratry Educatr COPD Outreach Prgram March, 2015 Disclaimer: The Canadian Fundatin fr Healthcare Imprvement (CFHI), in partnership

More information

Evaluation of Hunter & New England HealthPathways

Evaluation of Hunter & New England HealthPathways Evaluatin f Hunter & New England HealthPathways 2 General Practice & Ambulatry Care Activity General Practice MBS data: In 2013 there were 3.3 millin patient attendances t 730 GPs in the HML regin, a 5.6%

More information

Emergency Department Performance Measures

Emergency Department Performance Measures Emergency Department Perfrmance Measures ACEP Clinical Emergency Data Registry () ACEP Campaign Centers fr Medicare and Medicaid Services (CMS) Medicare Beneficiary Quality Imprvement Prject (MBQIP) ED

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential

More information

Appendix C SCHEDULE OF BENEFITS FOR THE LOW COST MEDICAL PLAN OF BENEFITS

Appendix C SCHEDULE OF BENEFITS FOR THE LOW COST MEDICAL PLAN OF BENEFITS Appendix C SCHEDULE OF BENEFITS FOR THE LOW COST MEDICAL PLAN OF BENEFITS The schedule n the fllwing pages highlights key features f the Lw Cst Medical Plan f Benefits fr Cvered Individuals. These benefits

More information

Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie

Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie 1 Rheumatid Arthritis Learning Cllabrative Spnsred by AMGF and AbbVie August 12-14, 2015 Ochsner Medical Center Best Practices in Managing patients with Rheumatid Arthritis 2 Medical Grup Prfile When was

More information

Solid Organ Transplant Benefits to Change for Texas Medicaid

Solid Organ Transplant Benefits to Change for Texas Medicaid Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a

More information

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder? updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health

More information

Meeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C

Meeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C Cmmnwealth f Kentucky Cabinet fr Health and Family Services Department fr Medicaid Services Drug Management Review Advisry Bard Meeting May 12, 2011 Meeting Minutes Vting Members in attendance: Kim Crley,

More information

Evidence Dossier to support COPD formulary decision making and guideline development

Evidence Dossier to support COPD formulary decision making and guideline development Evidence Dssier t supprt COPD frmulary decisin making and guideline develpment Prescribing and adverse event reprting infrmatin can be fund n the final pages f this dcument. Anr and Ellipta Trademarks

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 24 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

APPENDIX A Certification of Advanced Disease:

APPENDIX A Certification of Advanced Disease: APPENDIX A Certificatin f Advanced Disease: Name: DOB: Member ID: Name f Palliative Care Prgram: A. General Criteria: Check each f the fllwing that apply (All needed fr eligibility). Patient wh is likely

More information

Do Not Cite. Draft for Work Group Review.

Do Not Cite. Draft for Work Group Review. D Nt Cite. Draft fr Wrk Grup Review. Pst-Acute Ischemic Strke Screening and Care Measure Bundle Measure Descriptin Percentage f patients aged 18 years and lder with a diagnsis f ischemic strke r transient

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive

More information

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)

More information

ANDREW BRAUNSTEIN. o MIT (3 degrees Computers / Management) o 25 years building Clinical Systems. o 6 Patents in Clinical Technologies

ANDREW BRAUNSTEIN. o MIT (3 degrees Computers / Management) o 25 years building Clinical Systems. o 6 Patents in Clinical Technologies ANDREW BRAUNSTEIN MIT (3 degrees Cmputers / Management) 25 years building Clinical Systems ClinLgica Real-Time Clinical Rule Engine fr Predictive Analytics / Clinical Risk Management HealthWyse handheld

More information

Risk factors in health and disease

Risk factors in health and disease Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk

More information

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in

More information

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least

More information

Humana Updates and Resources

Humana Updates and Resources Humana Updates and Resurces Kelsey White and Janna Schmidt Prvider Cnsultants September 28 th 2018 Agenda Medicare CMS Stars HEDIS Stars Measures Patient Safety Part D Measures Member Experience CAHPS/HOS

More information

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES. Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC

More information

Survey Among the AvMed Physician Network

Survey Among the AvMed Physician Network Survey Amng the AvMed Physician Netwrk May 2018 Thank yu fr participating in this survey amng dctrs and staff wh are invlved and wrk with AvMed and ther health plans. If yu d NOT wrk with AvMed at the

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information

A. Catalonia World Health Organization Demonstration Project

A. Catalonia World Health Organization Demonstration Project A. Catalnia Wrld Health Organizatin Demnstratin Prject In 1989, the Health Department f Catalnia (Spain) and the Cancer Unit at the WHO (Geneva) designed and planned a demnstratin prject fr implementatin

More information

BANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION

BANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION BANKMED MEDICAL SCHEME MEDICINE ADVISORY SERVICES (Chrnic Medicine Benefit) GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Cnditins cvered under Bankmed s chrnic medicatin benefit are detailed belw. REGISTRATION

More information

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses

More information

CDC Influenza Division Key Points December 9, 2016

CDC Influenza Division Key Points December 9, 2016 In this dcument: Summary Key Pints Summary f Influenza Virus Labratry Data FluView Activity Update Early Influenza Vaccine Cverage Estimates fr 2016-17 Influenza Vaccine Prgram Impact Estimates fr 2015-16

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE

More information

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience

More information

CDC Influenza Division Key Points November 7, 2014

CDC Influenza Division Key Points November 7, 2014 In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates

More information

Low Molecular Weight Heparin Prescribing and Administration (Adults)

Low Molecular Weight Heparin Prescribing and Administration (Adults) Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight

More information

18 th Annual Citi Not-for-Profit Health Care Investor Conference. Managing Change

18 th Annual Citi Not-for-Profit Health Care Investor Conference. Managing Change 18 th Annual Citi Nt-fr-Prfit Health Care Investr Cnference Managing Change May 24, 2017 Presenters: Richard P. Miller President and Chief Executive Officer Rbert M. Segin Executive Vice President and

More information

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD) Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class

More information

Page 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided

Page 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided Page 1 f 5 NSABP B-47 - A Randmized Phase III Trial f Adjuvant Therapy Cmparing Chemtherapy Alne (Six Cycles f Dcetaxel Plus Cyclphsphamide r Fur Cycles f Dxrubicin Plus Cyclphsphamide Fllwed by Weekly

More information

Obesity/Morbid Obesity/BMI

Obesity/Morbid Obesity/BMI Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin

More information

Echocardiography Diagnostic Accuracy

Echocardiography Diagnostic Accuracy Echcardigraphy Diagnstic Accuracy Measure Descriptin: The prprtin f ptentially preventable and clinically imprtant inaccurate diagnses amng cngenital heart surgical patients. Numeratr Number f cngenital

More information